2024 Partners - Autoimmunity Pharma & Biotech Partnering Summit

Partners

Oppenheimer’s Healthcare Investment Banking Group consists of dedicated financial and healthcare industry veterans focused on life sciences, medical technology, and healthcare services sectors. We have extensive experience serving as both sell-side and buy-side advisors as well as in underwriting and placing equity and debt offerings for public and privately-held companies. Over the last decade, our healthcare banking professionals have completed financings totaling ~$30 billion and advised on over 300 M&A deals valued at ~$13 billion.

Website: www.oppenheimer.com

Pipeline Innovation Partner

Abacus is developing a humanized agonist antibody to CD180, a non-classical toll-like receptor (TLR) expressed by antigen-presenting cells. CD180 counterbalances proinflammatory mediators in the type 1 interferon (IFN) pathway. Anti-CD180 antibodies down-regulate TLR7/9 expression, attenuate signaling by the TLR7/9 and IFN receptors, and suppress downstream genes induced by TLR7/9 and IFNa. Anti-mouse CD180 is efficacious in murine models of lupus. As such, anti-human CD180 represents a differentiated opportunity to control rheumatic autoimmune diseases.

Website: www.abacusbioscience.com

Pipeline Innovation Partner

IASO Bio is developing CAR-Ts and biologics against liquid tumors and autoimmune diseases. Its fully human BCMA CAR-T, Fucaso, is approved in China for MM, and has shown excellent long-term efficacy in 7 AIDs in China IIT studies. Its fully human CD19 mAb, currently in phase I trial, has also shown better B-cell depletion efficacy than benchmark CD19 mAbs. Its BAFFR/CD3 TCE likewise showed excellent B cell depletion capability in vivo, including in the spleen.

Website: www.iasobio.com

Pipeline Innovation Partner

RheumaGen is engineering a cure for rheumatoid arthritis (RA), multiple sclerosis (MS), and other major autoimmune diseases using HLA gene editing. Our approach builds upon clinically proven methods to collect and edit hematopoietic stem cells which allow us to safely transform harmful HLA alleles into healthy ones. RheumaGen has received excellent initial FDA feedback and is preparing an IND submission to begin Phase I with refractory RA patients in Q4 2025.

Website: www.rheumagen.com

View Agenda

Buy Ticket

To the top

Partners

VENUE

LOCATION

OUR CONTACT DETAILS

JOIN OUR TEAM

ABOUT US

EXPLORE OUR PRODUCTS

SEARCH